TrialInvestigational new drugs2022

A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma.

Hani Babiker et al.PubMed ↗Publisher ↗

No numbers read from the abstract.